These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1915427)

  • 1. Comparison of hormonal and haemodynamic changes after long-term oral therapy with pimobendan or enalapril--a double-blind randomized study.
    Erlemeier HH; Kupper W; Bleifeld W
    Eur Heart J; 1991 Aug; 12(8):889-99. PubMed ID: 1915427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. The Pimobendan-Enalapril Study Group.
    Remme WJ; Krayenbühl HP; Baumann G; Frick MH; Haehl M; Nehmiz G; Baiker W
    Eur Heart J; 1994 Jul; 15(7):947-56. PubMed ID: 7925517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure.
    Pacher R; Stanek B; Globits S; Berger R; Hülsmann M; Wutte M; Frey B; Schuller M; Hartter E; Ogris E
    Eur Heart J; 1996 Aug; 17(8):1223-32. PubMed ID: 8869864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acute and long-term effects of pimobendan (UD-CG 115) in NYHA II and III heart failure. Results of a randomized multicenter double-blind study].
    Assmann I; Kassel P; Duck HG; Fiehring H; Morgan P; Schmidt PK; Höfs T; Nehmiz G
    Z Kardiol; 1991 Nov; 80(11):687-94. PubMed ID: 1792811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure.
    Katz SD; Kubo SH; Jessup M; Brozena S; Troha JM; Wahl J; Cohn JN; Sonnenblick EH; LeJemtel TH
    Am Heart J; 1992 Jan; 123(1):95-103. PubMed ID: 1729854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pimobendan (UDCG 115 BS) in long-term therapy of chronic heart failure].
    Bergler-Klein J; Globits S; Stefenelli T; Mayr H; Porenta G; Sochor H; Glogar D
    Z Kardiol; 1992 Oct; 81(10):546-52. PubMed ID: 1441695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized cross-over study of enalapril in congestive heart failure: haemodynamic and hormonal effects during rest and exercise.
    Mulligan IP; Fraser AG; Tirlapur V; Lewis MJ; Newcombe RG; Henderson AH
    Eur J Clin Pharmacol; 1988; 34(4):323-31. PubMed ID: 2841136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular effects and plasma level profile of pimobendan (UD-CG 115 BS) and its metabolite UD-CG 212 in patients with congestive heart failure after single and repeated oral dosing.
    Hagemeijer F; Brand HJ; Roth W
    J Cardiovasc Pharmacol; 1989 Aug; 14(2):302-10. PubMed ID: 2476606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy and safety of pimobendan in treatment of heart failure--experience in Japan.
    Kato K
    Cardiology; 1997; 88 Suppl 2():28-36. PubMed ID: 9142433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state.
    Cleland JG; Dargie HJ; Ball SG; Gillen G; Hodsman GP; Morton JJ; East BW; Robertson I; Ford I; Robertson JI
    Br Heart J; 1985 Sep; 54(3):305-12. PubMed ID: 2994698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.
    Fitton A; Brogden RN
    Drugs Aging; 1994 May; 4(5):417-41. PubMed ID: 8043944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group.
    Kubo SH; Gollub S; Bourge R; Rahko P; Cobb F; Jessup M; Brozena S; Brodsky M; Kirlin P; Shanes J
    Circulation; 1992 Mar; 85(3):942-9. PubMed ID: 1537130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of enalapril on clinical status, biochemistry, exercise performance and haemodynamics in heart failure.
    Webster MW; Fitzpatrick MA; Hamilton EJ; Nicholls MG; Ikram H; Espiner EA; Wells JE
    Drugs; 1985; 30 Suppl 1():74-81. PubMed ID: 2994990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Reduction in left ventricular volume and improvement in hemodynamics following intravenous administration of pimobendan (UDGG 115 BS) in dilated cardiomyopathy].
    Permanetter B; Sebening H; Busch U; Lutilsky L
    Z Kardiol; 1990 Aug; 79(8):565-72. PubMed ID: 2220013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enalapril in congestive heart failure: acute hemodynamic and neurohumoral evaluation and short-term follow-up.
    Lin M; Chiang HT; Chang MS; Kong CW; Wang SP; Chiang BN
    Zhonghua Yi Xue Za Zhi (Taipei); 1991 Jul; 48(1):31-40. PubMed ID: 1679372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of a reduction in haemoglobin concentration by enalapril in stable, moderate heart failure: a double blind study.
    Herrlin B; Nyquist O; Sylvén C
    Br Heart J; 1991 Sep; 66(3):199-205. PubMed ID: 1931347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemodynamic and clinical response to enalapril, a long-acting converting-enzyme inhibitor, in patients with congestive heart failure.
    Levine TB; Olivari MT; Garberg V; Sharkey SW; Cohn JN
    Circulation; 1984 Mar; 69(3):548-53. PubMed ID: 6319045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute hemodynamic effects and preload-dependent cardiovascular profile of the partial phosphodiesterase inhibitor nanterinone in patients with mild to moderate heart failure.
    Remme WJ; van der Ent M; Bartels GL; van Schelven D; van Hoogenhuyze DC; Krauss XH; Kruijssen HA; Storm CJ
    Cardiovasc Drugs Ther; 1996 May; 10(2):137-44. PubMed ID: 8842505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute and long-term hemodynamic effects of pimobendan (UD-CG 115 BS) in comparison with captopril.
    Hauf GF; Grom E; Jähnchen E; Roskamm H
    J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S49-56. PubMed ID: 2478793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlations between the cardiovascular effects of pimobendan and plasma concentrations of the parent compound and of its major active metabolite, UD-CG 212 CL, in patients with congestive heart failure.
    Hagemeijer F; Roth W; Brand HJ
    J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S57-64. PubMed ID: 2478794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.